Zheng Yuantong, Chen Xinyi, Huang Yunfei, Lin Xuanli, Lin Jiaxin, Mo Yuting, Gan Lu, Wei Shuhua, Wang Zhen, Song Xiaojuan, Tu Zhengchao
College of Pharmacy, Jinan University, Guangzhou 510006, Guangdong, PR China.
College of Pharmacy, Jinan University, Guangzhou 510006, Guangdong, PR China; State Key Laboratory of Bioactive Molecules and Druggability Assessment, International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development (MOE), School of Pharmacy, Jinan University, Guangzhou 510632, PR China.
Int J Biol Macromol. 2025 Jun;313:144388. doi: 10.1016/j.ijbiomac.2025.144388. Epub 2025 May 19.
DDX27, a member of the DEAD-box RNA helicase family, plays a crucial role in RNA metabolism, inflammation, and cancer progression. Elevated expression of DDX27 has been observed in multiple cancers, including oral squamous cell carcinoma (OSCC), breast cancer (BC), colorectal cancer (CRC), gastric cancer (GC), and hepatocellular carcinoma (HCC), where it is associated with poor prognosis, tumor growth, metastasis, and chemoresistance. DDX27 regulates the NF-κB signaling pathway, which is central to inflammation and tumor progression, and influences key cellular processes such as cell cycle regulation, apoptosis, migration, and stemness. Additionally, DDX27 promotes epithelial-mesenchymal transition (EMT), further contributing to metastasis. Its interactions with non-coding RNAs and various signaling pathways complicate treatment responses, making DDX27 a promising therapeutic target. This review explores the role of DDX27 as both a biomarker and therapeutic target, with potential strategies including small molecule inhibitors, RNA interference, and combination therapies with existing treatments such as NF-κB inhibitors or chemotherapy. Targeting DDX27 may help overcome resistance, reduce metastasis, and improve cancer treatment outcomes. Further research into its molecular mechanisms and interactions will be crucial for developing effective therapies, particularly for cancers with high metastatic potential.
DDX27是DEAD盒RNA解旋酶家族的成员之一，在RNA代谢、炎症和癌症进展中起着关键作用。在多种癌症中都观察到DDX27表达升高，包括口腔鳞状细胞癌（OSCC）、乳腺癌（BC）、结直肠癌（CRC）、胃癌（GC）和肝细胞癌（HCC），在这些癌症中它与预后不良、肿瘤生长、转移和化疗耐药相关。DDX27调节NF-κB信号通路，该通路在炎症和肿瘤进展中至关重要，并影响细胞周期调控、凋亡、迁移和干性等关键细胞过程。此外，DDX27促进上皮-间质转化（EMT），进一步促进转移。它与非编码RNA和各种信号通路的相互作用使治疗反应复杂化，使DDX27成为一个有前景的治疗靶点。本综述探讨了DDX27作为生物标志物和治疗靶点的作用，潜在策略包括小分子抑制剂、RNA干扰以及与现有治疗方法（如NF-κB抑制剂或化疗）的联合治疗。靶向DDX27可能有助于克服耐药性、减少转移并改善癌症治疗结果。对其分子机制和相互作用的进一步研究对于开发有效的治疗方法至关重要，特别是对于具有高转移潜力的癌症。
